Navigation Links
European Society for Medical Oncology and European CanCer Organization join forces
Date:4/9/2008

Lugano, Switzerland and Brussels, Belgium, 9 April 2008: The European Society for Medical Oncology (ESMO) and ECCO - the European CanCer Organisation have united forces to host a co-branded biennial multidisciplinary partnership meeting that will provide the best and most updated scientific data for everyone working in cancer and will also strengthen initiatives aimed at providing all cancer patients with equal access to high-quality cancer care.

The ECCO Congress, which takes place every two years, will become a joint ECCO-ESMO congress, and its scientific committee will be chaired both by ECCO and ESMO. The first congress will be 20-24 September 2009 in Berlin, with subsequent joint congresses being held biennially in the uneven-numbered years.

In the intervening even-numbered years between the ECCO-ESMO congresses, ESMO will continue to hold its own ESMO Congress. In 2008, the 33rd ESMO Congress will take place as planned, 12-16 September, in Stockholm, Sweden.

In addition, ESMOs Board of Directors unanimously voted on 4 April to become a founding member of the new ECCO organisation, composed of European cancer societies, and as a result, ESMO will have a seat on the ECCO Board of Directors. The ECCO Board unanimously accepted the proposal two weeks ago.

ECCO President, Professor Alexander M.M. Eggermont, said he was delighted. ESMO and ECCO have been discussing this for some time now, and we firmly believe that joining forces in this way will benefit all our member organisations, European cancer professionals and, most importantly, cancer patients.

With so much happening in Europe affecting advances in oncology, we need to work together when interacting with European policymakers and industry, so that they take notice, understand and act on our messages. ECCOs mission is to uphold the right of all cancer patients to the best possible treatment and care and to promote interaction between all organisations involved in cancer research, education, treatment and care at the European level. Together with ESMO, I am confident that we will be able to achieve this goal.

ESMO President, Professor Jos Baselga agreed, and added: This uniting of the landscape of European oncology is the result of an agreement on common goals combined with a strong spirit of goodwill and collaboration on all sides. In becoming a founding member of ECCO, we are convinced we will strengthen our ability to represent European oncologists and patients. ESMO is a community of professionals who share the common goal of providing the best possible care for all cancer patients a mission which is in total harmony with ECCOs objectives.

This is a win-win situation for ESMO, ECCO and all of our patients. I am looking forward to liaising closely with Professor Eggermont, not only in supporting medical oncology and cancer treatment by multidisciplinary teams, but also in working towards enhancing European conferences as attractive settings to present research done in Europe and worldwide. Looking ahead, we will combine our efforts to make the 2009 ECCO 15 34th ESMO Congress the best and biggest European cancer congress yet.


'/>"/>

Contact: Emma Mason
wordmason@mac.com
07-711-296-986
ECCO-the European CanCer Organisation
Source:Eurekalert

Related medicine news :

1. FORSTEO(R) Receives Approval from the European Commission for the Treatment of Glucocorticoid-Induced Osteoporosis
2. Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation
3. IOF recognizes ESCEO European guidance for osteoporosis diagnosis and management
4. More Clinical Data Required to Support European Approval of Desvenlafaxine as a Potential Treatment for Vasomotor Symptoms
5. Gene expression differences between Europeans and Africans affect response to drugs, infections
6. Space sentinels: New tools in space to improve European environment and security policies
7. Boston Scientific Announces First European Implants of New Devices to Treat Heart Failure and Sudden Cardiac Death
8. Specialty European Pharma launches plenaxis in Germany
9. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
10. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
11. European Neuroscience and Society Network tackles neurosocieties head-on
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... The ... announced it has signed a letter of intent with Moda to ... Insurance Company (NORDIC). , Started by dentists 36 years ago, TDIC focuses exclusively ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic ... Western Championships. The competition will be held at the University of Montana on April ... west of the Mississippi River. , In order to qualify, Varize needed to place ...
(Date:4/28/2016)... WASHINGTON, D.C., (PRWEB) , ... April 28, 2016 ... ... health systems, and the Campaign for Tobacco-Free Kids, a leading force in the ... to promote federal, state and local policies that can help reduce tobacco use. ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... Management solutions, announces today the availability of its latest software release, NetZoomDC ... capacity management and optimization, providing new analytical capabilities that assess complex capacity ...
(Date:4/28/2016)... ... April 28, 2016 , ... The American ... and Anzu®, developers of the AnzuMedical™ Knowledge Sharing and Collaboration Platform™ , ... Network. The platform is scheduled to launch in July 2016 and will be ...
Breaking Medicine News(10 mins):
(Date:4/26/2016)... -- US demand for infection prevention products and ... to $27.6 billion in 2020.  Increasing pressures on ... of healthcare-associated infections (HAIs) will boost revenues generated ... declining, the overall rate of certain HAIs in ... the CDC.  Recent statistics indicate that only 25 ...
(Date:4/26/2016)... April 26, 2016 Bayer AG ... interest, taxes, depreciation and amortization. The earnings are the ... multinational,s best-selling drugs Xarelto and Eylea, drugs Bayer is ... Xarelto,s patent expiration date was extended by four years ... market is expected to reach a value of ...
(Date:4/26/2016)... YORK , April 26, 2016 /PRNewswire/ ... report "Global Microbial identification Market Size, Share, ... - Industry Insights by Product (Consumables, Instruments ... Method and Genotypic Method), by Application (Diagnostic ... and Environmental Application) and by End User ...
Breaking Medicine Technology: